Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesStevanato Group SpA

Stevanato Group SpA

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
13.91 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1039728
Market Cap
5880.50M
P/E
37.14

Momentum Score

…

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.70
Low
14.11
High
52 Week Price Range
12.84
Low
27.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
13.91
Dividend Yield
-
Revenue TTM
1225.23M
Revenue Per Share
4.49
Gross Profit TTM
360.21M
Debt / Equity
0.32
ROE
9.13%
Net Debt
340.16M
ROCE
10.13%
Diluted EPS TTM
0.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 181.64M 160.29M 189.55M 187.60M 165.70M
Minority interest 0.01M 0.01M -0.02M -0.17M 0.05M
Net income 134.28M 117.78M 145.63M 143.00M 134.30M
Selling general administrative 119.06M 93.75M 88.95M 85.70M 62.50M
Selling and marketing expenses - 24.85M 24.98M 26.10M 20.40M
Gross profit 330.33M 302.32M 339.89M 319.80M 265.40M
Reconciled depreciation 88.57M 80.65M 75.49M 64.82M 56.38M
Ebit 203.44M 167.15M 193.87M 152.58M 128.12M
Ebitda 288.54M 247.80M 272.35M 217.40M 184.50M
Depreciation and amortization 85.10M 80.65M 78.48M 64.82M 56.38M
Operating income 183.08M 161.14M 200.72M 152.58M 128.12M
Other operating expenses 956.40M 942.89M 884.63M 791.30M 681.60M
Interest expense 21.80M 6.86M 4.32M 29.80M 18.80M
Tax provision 49.27M 42.52M 45.79M 44.60M 31.40M
Interest income 1.03M 1.72M 0.81M 25.00M 0.57M
Net interest income -5.76M -5.84M -3.29M -4.80M -4.51M
Income tax expense 47.35M 42.52M 43.86M 44.60M 31.40M
Total revenue 1139.48M 1104.04M 1085.35M 983.70M 843.90M
Total operating expenses 147.25M 141.18M 139.17M 127.40M 103.10M
Cost of revenue 809.15M 801.72M 745.46M 663.90M 578.50M
Total other income expense net -1.44M -0.85M -11.17M 35.02M 37.58M
Net income from continuing ops 139.83M 117.77M 148.80M 143.00M 134.27M
Net income applicable to common shares - - - 142.85M 134.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2542.92M 2328.82M 2071.58M 1659.47M 1418.47M
Intangible assets 36.85M 33.59M 30.98M 32.16M 31.93M
Other current assets -8.60M 6.77M 13.74M 6.35M 0.44M
Total liab 1056.95M 924.43M 938.93M 663.79M 577.18M
Total stockholder equity 1485.87M 1404.34M 1132.53M 995.90M 841.70M
Deferred long term liab - - - 4.63M 7.33M
Other current liab 106.91M 57.79M 65.51M 111.94M 88.70M
Common stock 22.22M 22.23M 21.70M 21.70M 21.70M
Capital stock 22.23M 22.23M 21.70M 21.70M 21.70M
Retained earnings 876.41M 863.44M 757.86M 26.00M 27.00M
Other liab - - - 52.88M 36.27M
Good will 49.96M 49.98M 49.98M 47.24M 47.24M
Other assets - - -1.00M 2.59M -0.40M
Cash 130.54M 98.27M 69.60M 228.74M 411.04M
Total current liabilities 535.57M 477.47M 574.39M 462.50M 338.62M
Current deferred revenue 43.78M 44.67M 58.80M 41.40M 42.40M
Net debt 340.16M 330.70M 326.99M -10.37M -166.75M
Short term debt 121.69M 111.93M 141.44M 69.96M 42.73M
Short long term debt 117.36M 106.84M 135.60M 64.63M 37.17M
Short long term debt total 470.70M 428.97M 396.59M 218.37M 244.29M
Other stockholder equity 532.26M 532.42M 362.08M 116.62M 106.95M
Property plant equipment - - - 660.69M 415.41M
Total current assets 934.40M 880.12M 861.89M 845.77M 865.97M
Long term investments 5.64M 5.64M 5.15M 1.83M 1.97M
Net tangible assets - - - 921.36M 770.23M
Short term investments 2.20M 0.00M 0.75M 27.91M 27.17M
Net receivables 542.17M 529.87M 522.48M 369.48M 278.42M
Long term debt 337.78M 305.23M 242.05M 133.75M 183.99M
Inventory 268.09M 245.22M 255.32M 213.30M 148.90M
Accounts payable 263.19M 231.02M 277.81M 239.20M 164.80M
Accumulated other comprehensive income 54.95M -13.75M -9.11M 831.58M 686.05M
Non currrent assets other 8.60M - 0.58M -0.02M 0.42M
Non current assets total 1608.52M 1448.70M 1209.68M 811.10M 552.90M
Capital lease obligations 13.76M 16.90M 18.95M 19.98M 23.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.25M -310.21M -425.65M -243.00M 15.59M
Change to liabilities - - - 36.05M 44.34M
Total cashflows from investing activities -262.15M -310.21M -421.22M -242.95M -96.43M
Net borrowings 36.80M 27.91M 172.57M -31.04M -120.18M
Total cash from financing activities 21.19M 183.22M 158.03M -44.50M 254.80M
Net income 134.32M 160.29M 189.55M 187.64M 165.67M
Change in cash 43.94M 28.67M -159.14M -182.30M 295.44M
Begin period cash flow 86.61M 69.60M 228.74M 411.04M 115.60M
End period cash flow 130.55M 98.27M 69.60M 228.74M 411.04M
Total cash from operating activities 274.79M 155.78M 105.21M 103.30M 133.30M
Issuance of capital stock 0.00M 169.77M 0.00M 0.00M 380.09M
Depreciation 83.90M 80.65M 78.48M 64.82M 56.38M
Other cashflows from investing activities 0.00M -7.44M 15.60M - -
Dividends paid 14.16M 14.46M 14.29M -13.50M -11.20M
Change to inventory -39.82M 12.31M -113.59M -107.37M -31.20M
Change to account receivables 0.86M -3.83M -93.86M -46.42M -54.77M
Sale purchase of stock - - - - 8.00M
Other cashflows from financing activities -6.03M - -0.25M 13.24M 6.13M
Change to netincome - - - 13.42M -14.79M
Capital expenditures 253.35M 313.57M 441.93M 243.13M 113.18M
Change in working capital 48.63M -17.41M -102.48M -117.74M -41.63M
Stock based compensation - - 1.98M - -
Other non cash items 7.94M -67.76M -60.34M -31.43M -47.12M
Free cash flow 21.44M -157.79M -336.72M -139.83M 20.12M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STVN
Stevanato Group SpA		 -
-%		 13.91 37.14 28.65 4.80 3.24 4.39 18.35
ISRG
Intuitive Surgical Inc		 0.21
0.05%		 450.25 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 -11.76
5.48%		 202.74 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -3.10
2.95%		 101.85 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 1.91
0.90%		 214.52 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Via Molinella 17, Piombino Dese, PD, Italy, 35017

39 04 99 31 811

https://www.stevanatogroup.com

6010

Name Title Year Born
Mr. Franco Stevanato Exec. Chairman 1973
Mr. Franco Moro CEO, COO & Director 1963
Mr. Marco Dal Lago Chief Financial Officer 1972
Mr. Paolo Patri Chief Technology Officer 1970
Ms. Lisa Miles Sr. VP of Investor Relations NA
Mr. Mauro Stocchi Chief Bus. Officer 1966
Mr. Riccardo Butta Pres of Americas NA
Mr. Franco Stevanato CEO & Executive Chairman 1973
Mr. Marco Dal Lago Chief Financial Officer 1973
Ms. Lisa Miles Chief Communications & Investor Relations Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…